Edition:
India

Onconova Therapeutics Inc (ONTX.OQ)

ONTX.OQ on NASDAQ Stock Exchange Capital Market

1.71USD
22 Nov 2017
Change (% chg)

$0.03 (+1.79%)
Prev Close
$1.68
Open
$1.67
Day's High
$1.71
Day's Low
$1.67
Volume
7,046
Avg. Vol
25,010
52-wk High
$3.88
52-wk Low
$1.46

Summary

Name Age Since Current Position

Michael Hoffman

66 2006 Chairman of the Board

Ramesh Kumar

59 1998 President, Chief Executive Officer, Director

Mark Guerin

47 2016 Chief Financial Officer

Steven Fruchtman

64 2015 Senior Vice President - Research and Development, Chief Medical Officer

Manoj Maniar

52 2005 Senior Vice President - Product Development

Henry Bienen

76 2009 Director

Jerome Groopman

63 2013 Director

Viren Mehta

65 2004 Director

E. Premkumar Reddy

71 1999 Director

Jack Stover

64 2016 Director

Anne VanLent

68 2013 Director

James Marino

67 2015 Independent Director

Biographies

Name Description

Michael Hoffman

Mr. Michael B. Hoffman serves as Chairman of the Board of Onconova Therapeutics, Inc., since 2006. He is a member of the board of directors since December 2002. Since 2003, Mr. Hoffman has been a managing director of Riverstone Holdings LLC, or Riverstone, where he is principally responsible for investments in power and renewable energy. Before joining Riverstone, Mr. Hoffman was senior managing director and head of the mergers and acquisitions advisory business of The Blackstone Group L.P., or Blackstone, where he also served on the firm's principal group investment committee as well as its executive committee. Prior to joining Blackstone, Mr. Hoffman was managing director and co-head of the mergers and acquisitions department at Smith Barney, Harris Upham & Co. Mr. Hoffman received his Bachelor's and Master's Degrees from Northwestern University and his M.B.A. from the Harvard Business School.

Ramesh Kumar

Dr. Ramesh Kumar, Ph.D., serves as President, Chief Executive Officer, Director of Onconova Therapeutics, Inc. Prior to founding the company, Dr. Kumar held positions in research and development or management at Princeton University, Bristol-Myers Squibb Company, or Bristol-Myers Squibb, DNX Corp. (later Nextran Corp., a subsidiary of Baxter International Inc.) and Kimeragen, Inc. (later ValiGen Inc.), a genomics company, where he was President of the Genomics and Transgenics Division. Dr. Kumar received his Ph.D. in Molecular Biology from the University of Illinois, Chicago, and trained at the National Cancer Institute. Additionally, Dr. Kumar received his B.Sc. and M.Sc., both with honors, in Microbiology from Panjab University.

Mark Guerin

Mr. Mark Guerin has been appointed as Chief Financial Officer of the Company, effective September 1, 2016. He has served as Vice President — Financial Planning & Accounting, and Chief Accounting Officer since May 2014, and as Vice President — Financial Planning & Accounting from September 2013 to May 2014. Between January 2012 and September 2013, Mr. Guerin was self-employed as a financial and accounting consultant. For more than six years, through December 2011, Mr. Guerin was employed by CardioKine, Inc., serving as Chief Financial Officer from mid-2009 through December 2011.

Steven Fruchtman

Dr. Steven M. Fruchtman, M.D., serves as Senior Vice President - Research and Development, Chief Medical Officer of the Company, since January 2015. Dr. Fruchtman is a board certified hematologist with extensive industry experience in clinical research for myelodysplastic syndromes, hematologic malignancies and solid tumors. From June 2014 to January 2015, Dr. Fruchtman was a hematology oncology drug development consultant. From September 2013 to June 2014, Dr. Fruchtman served as Chief Medical Officer at Syndax Pharmaceuticals, Inc., a biopharmaceutical company. From July 2011 to July 2013, Dr. Fruchtman was the Chief Medical Officer and Senior Vice President of Research and Regulatory Affairs at Spectrum Pharmaceuticals. From February 2011 to June 2011, he was Vice President of Research at Spectrum Pharmaceuticals, Inc., a biopharmaceutical company. From February 2009 to January 2011, Dr. Fruchtman was Vice President, Clinical Research at Allos Therpeutics, Inc., a biopharmaceutical company. Prior to this, Dr. Fruchtman held senior positions at Novartis and Ortho Biotech Products. Dr. Fruchtman was on the faculty of the Mount Sinai School of Medicine and was the Director of the Stem Cell Transplantation and Myeloproliferative Disorder Programs at Mount Sinai Hospital in New York City. Dr. Fruchtman received his medical degree from New York Medical College and his B.A. from Cornell University.

Manoj Maniar

Dr. Manoj Maniar, Ph.D., serves as Senior Vice President - Product Development of Onconova Therapeutics, Inc. Prior to joining the Company, Dr. Maniar was with SRI International, Inc., a nonprofit research institute, where he served as Senior Director, Formulations and Drug Delivery. Dr. Maniar received his B.S. in Pharmacy from Bombay College of Pharmacy and his Ph.D. in Pharmaceutics from the University of Connecticut.

Henry Bienen

Dr. Henry S. Bienen, Ph.D., serves as Director of Onconova Therapeutics, Inc., since May 2009. He currently serves as the chairman of Rasmussen College, has served as the president emeritus of Northwestern University since 2009 and served as the president of Northwestern University from 1995 to 2009. Dr. Bienen was the James S. McDonnell Distinguished University Professor and Dean of the Woodrow Wilson School of Public and International Affairs at Princeton University prior to his appointment at Northwestern. Dr. Bienen began his association with Princeton University in 1966, advancing from assistant professor to professor of politics and international affairs, and was then appointed the William Stewart Tod Professor of Politics and International Affairs in 1981 and the James S. McDonnell Distinguished University Professor in 1985. Dr. Bienen has served as a director of Gleacher & Company, a publicly held investment banking firm, since May 2010, and the Grosvenor Registered Multi Strategy Fund (TI 1), LLC, the Grosvenor Registered Multi Strategy Fund (TI 2), LLC, the Grosvenor Registered Multi Strategy Fund (TE), LLC and the Grosvenor Registered Multi Strategy Master Fund, LLC since April 2011. Dr. Bienen previously served on the boards of directors of The Bear Stearns Companies Inc. until its purchase by JP Morgan Chase & Co. in 2008, and SPSS Inc. from 2007 until 2009, when the company was sold to IBM Corporation. Dr. Bienen received his Bachelor's Degree with honors from Cornell University and both his Master's Degree and Ph.D., from the University of Chicago.

Jerome Groopman

Dr. Jerome E. Groopman, M.D. has been appointed as Director of Onconova Therapeutics, Inc., effective July 25, 2013. Dr. Groopman has served as the Dina and Raphael Recanati Professor of Medicine at Harvard Medical School since January 1992. He has also served as Attending Hematologist/Oncologist at Beth Israel Deaconess Medical Center since July 1996. Dr. Groopman received an M.D. from Columbia University College of Physicians and Surgeons, and a B.A. in Political Philosophy from Columbia College.

Viren Mehta

Dr. Viren Mehta, Ph.D., serves as Director of Onconova Therapeutics, Inc., since February 2004. Dr. Mehta has been a managing member of Mehta Partners since 1997. Mehta Partners provides strategic advisory services to the biotechnology and pharmaceutical companies worldwide. Prior to founding Mehta Partners, Dr. Mehta co-founded Mehta and Isaly in 1989, and prior to that was a part of the strategic planning team of the International Division at Merck & Co., or Merck. Dr. Mehta earned a Doctor of Pharmacy at the University of Southern California, and an M.B.A. from the Anderson School of Business at the University of California, Los Angeles.

E. Premkumar Reddy

Dr. E. Premkumar Reddy, Ph.D., serves as Director of Onconova Therapeutics, Inc., since February 1999. Since March 2010, Dr. Reddy has served as a Professor and Director of the Experimental Cancer Therapeutics Program at Mount Sinai School of Medicine, or Mount Sinai. From 1992 to February 2010, Dr. Reddy served as a Professor and Director of the Fels Institute for Cancer Research of Temple University. He was the founder and co-editor of the international journal of cancer research, Oncogene, published by Nature Publishing Group. Dr. Reddy received his B.Sc., M.Sc. and Ph.D. from Osmania University.

Jack Stover

Mr. Jack E. Stover is Director of the Company. He serves as Interim President, CEO and Director of Interpace Diagnostics Group Inc., a company that provides clinically useful molecular diagnostic tests and pathology services for evaluating the risks of thyroid and pancreatic cancer. Prior to his tenure at Interpace Diagnostics Group he served from August 2005 until December 2015 as Director, Member of the Special Executive Committee and Chairman of the Audit Committee of PDI Inc. (PDI), an outsourced promotional services and contract sales company serving the pharmaceutical and biotechnology industry. In December 2015, PDI was purchased by Publicis Touchpoint Solutions. In addition to his current position at Interpace Diagnostics Inc., Mr. Stover has served as President of Zebec Therapeutics, the successor to Quandrant Pharma, a position he has held since September 2012. Zebec is a privately held, virtual pharmaceutical company focused on acquiring and repositioning branded and generic products with predictable cash flows and managing product life cycles. Mr. Stover formerly served as Executive Chairman of Targeted Nano Therapeutics from November 2008 to August 2012. He also served as Chief Executive Officer and Director of Antares Pharma Inc., a publicly traded specialty pharmaceutical company, from June 2004 to November 2008. Mr. Stover joined Antares as President and COO. He led the transition from a platform based device company to a product based company. Mr. Stover joined Antares Pharma from SICOR Inc., which was subsequently sold to Teva Pharmaceuticals for $3.5 billion. At SICOR, Inc., he served as Executive Vice President, Chief Financial and Operating Officer and Treasurer. For over 15 years prior, Mr. Stover was an employee of PricewaterhouseCoopers (previously Coopers & Lybrand), serving as a partner for over five years. He is a certified public accountant and received his Bachelor's Degree in Accounting and Finance from Lehigh University.

Anne VanLent

Ms. Anne M. VanLent has been appointed as Director of Onconova Therapeutics, Inc., effective July 25, 2013. She has served as President of AMV Advisors, a personal consulting firm providing strategic and financial services to companies in the greater life sciences sector, since May 2008. Ms. VanLent has also served as a director and chair of the audit committee of Biota Pharmaceuticals, Inc. since May 2013, Aegerion Pharmaceuticals, Inc. since April 2013 and Ocera Therapeutics, Inc. since March 2011. From December 2004 to May 2013, Ms. VanLent was a director of Integra Life Sciences Holding Corporation, serving as a member of the audit committee from December 2004 to May 2013 and as its chair from May 2006 to May 2012, as well as serving as a member of the compensation committee from 2005 to 2006. From 1998 to 2010, Ms. VanLent served as a director of Penwest Pharmaceuticals Co., where she was chair of the audit committee between 1999 and 2010 as well as chair of the nomination and governance committee from 2008 to 2010. Ms. VanLent received a B.A. degree in Physics from Mount Holyoke College.

James Marino